Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $780,712 - $1.3 Million
18,400 Added 90.2%
38,800 $2.64 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $743,940 - $1.34 Million
18,000 Added 750.0%
20,400 $861,000
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $343,247 - $449,997
-6,100 Reduced 71.76%
2,400 $165,000
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $1.47 Million - $1.89 Million
-24,900 Reduced 74.55%
8,500 $628,000
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $586,866 - $881,456
8,900 Added 36.33%
33,400 $2.28 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $858,716 - $1.3 Million
13,700 Added 126.85%
24,500 $2.3 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $184,041 - $276,003
3,900 Added 56.52%
10,800 $732,000
Q4 2022

Feb 14, 2023

SELL
$30.35 - $53.15 $312,605 - $547,445
-10,300 Reduced 59.88%
6,900 $341,000
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $549,884 - $849,164
17,200 New
17,200 $559,000
Q2 2020

Aug 14, 2020

SELL
$55.75 - $92.75 $473,875 - $788,375
-8,500 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $68,220 - $187,992
-1,800 Reduced 17.48%
8,500 $493,000
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $2.18 Million - $2.8 Million
-28,100 Reduced 73.18%
10,300 $953,000
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $1.47 Million - $2 Million
16,300 Added 73.76%
38,400 $3.47 Million
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $438,599 - $578,396
4,900 Added 28.49%
22,100 $2.61 Million
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $1.07 Million - $1.66 Million
17,200 New
17,200 $1.49 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.